Amiti Ventures joins pharma venture studio AION Labs as a Strategic Partner
Amiti Ventures joins pharma venture studio AION Labs as a Strategic Partner
The Israeli VC firm joins the Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund, BioMed X and Amazon Web Services
AION Labs, a venture studio focusing on the adoption of AI and computational science to solve therapeutic challenges, has announced a new strategic partnership with Israeli early-stage VC firm Amiti Ventures.
AION Labs builds and invests in early-stage startup teams focused on AI and biology in drug discovery and development, offering resources and mentorship. The partnership between the two parties will help advance healthcare towards more patient-centric precision medicine and help bring new treatments to market. The venture includes companies like AstraZeneca, Merck, Pfizer, Teva, the Israel Biotech Fund, and Amazon Web Services (AWS), and is powered by BioMed X with the support of the Israeli Government via the Israel Innovation Authority,
"With a proven track record of identifying the best teams for the mission and investing early in the most innovative deep tech startups that shape the future, Amiti Ventures will bring important complementary capabilities and expert investor knowledge to the AION Labs partnership," said Mati Gill, CEO of AION Labs.
The addition of Amiti Ventures means that AION Labs will improve its expertise and capabilities in deep tech and computational technology domains - areas that are critical for the success of biotech innovation.
"We believe that AION Labs is uniquely positioned to identify the biggest challenges to accelerate drug discovery and development and then evaluate the best computational bio approaches and entrepreneurs,” added Ben Rabinowitz, Founder and Managing Partner of Amiti Ventures. “AION Labs' venture studio model bridges the gap between outstanding academic research, huge leaps forward in generative AI, and the biggest challenges and opportunities in the development of new medicines, and we look forward to working closely with our new partners to make this a reality.”
Amiti Ventures is an Israeli deep tech venture capital firm looking for Seed-stage outlier companies that develop transformative technologies. Its primary targets include quantum computing and computational and synthetic biology.
